October 4, 2021/Cancer/Research

Sarcoma: Continuing the Search for Treatment Alternatives

Current trials study novel therapies for rhabdomyosarcoma and clear cell sarcoma

21-ORI-2348541 650×450 picture bone sarcoma-A

Treatment options for many sarcomas haven’t moved forward in decades. In many cases, clinicians are still using the same chemotherapies first developed a generation ago. But that may be starting to change.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Several new clinical trials at Cleveland Clinic are part of an effort to find better treatment options for a variety of sarcomas.

Current therapies tend to be highly toxic and not universally effective says Cleveland Clinic pediatric oncologist Matteo Trucco, MD. For decades, treatment focused on simply pushing chemotherapy doses higher and higher. But those strategies eventually plateaued.

“For the last 10 years or so, we’ve been trying to find therapeutic alternatives,” he says. “A lot of that started in the lab and is finally reaching maturation. Now we’re finally bringing these treatments to patients.”


Different treatments for different sarcomas

Historically, sarcomas have been understudied compared to other tumors, notes Cleveland Clinic medical oncologist Dale Shepard, MD, PhD. Trials often grouped together many different sarcomas, taking a one-size-fits-all approach to treatment, often with poor results.

“Both researchers and clinicians are getting away from lumping sarcomas together and instead are treating them as the individual diseases they are,” he says.

A sarcoma dream team

Cleveland Clinic’s multidisciplinary team of specialists has made it a leader in sarcoma treatment and research, adds Dr. Shepard. Those specialists include radiologists, medical oncologists, radiation oncologists, pediatric oncologists, orthopaedic surgeons and a nationally recognized pathology lab, all focused on sarcoma treatment.


“It’s a dream team of people who specialize in these tumor types,” says Dr. Trucco.

Current trials

Current sarcoma research at Cleveland Clinic includes these two trials being led or co-led by Dr. Trucco:

  1. Evolutionary inspired therapy for newly diagnosed metastatic fusion-positive rhabdomyosarcoma
    Sponsor/Collaborator: H. Lee Moffitt Cancer Center & Research Institute; National Pediatric Cancer Foundation

    Summary: Metastatic fusion-positive rhabdomyosarcoma responds well to initial treatment, but 94% of patients relapse within three years, after which the disease becomes much more difficult to treat. This study will look at whether attacking the cancer with different schedules and combinations of chemotherapy is more effective than repeatedly using the same drugs at high doses, applying principles of evolution to attempt to outsmart the cancer and make it “extinct.”

    Eligibility: Any newly diagnosed patient with metastatic fusion-positive rhabdomyosarcoma

  2. Devimistat and hydroxychloroquine for clear cell sarcoma
    Sponsor: Rafael Pharmaceuticals

    Summary: Clear cell sarcoma is extremely rare and has an extremely poor prognosis. A small paper in Japan showed that in a mouse model, the drugs devimistat and chloroquine in combination dramatically blocked the sarcoma growth — even though each drug alone had little effect. This trial was inspired by the patient community, after the family of a patient found the paper and asked that their son receive the treatment via compassionate use. While this patient received the treatment when he already had end-stage disease, it inspired support for a clinical trial of the combination of devimistat and the more tolerable hydroxychloroquine for patients earlier in their disease course, when it is more likely to be beneficial.

    Eligibility: Patients age 11 to 75 with relapsed clear cell sarcoma or other relapsed fusion-positive sarcomas

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 1, 2024/Cancer/Research
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024/Cancer/Research
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023/Cancer/Research
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy